AcquisitionsMay 5, 2026, 12:32 PM
Curaleaf Completes Buyout of Remaining 45% Stake in Four 20 Pharma
AI Summary
Curaleaf Holdings, Inc. has completed the acquisition of the remaining 45% stake in Four 20 Pharma GmbH, a leading German medical cannabis producer and distributor. This full buyout strengthens Curaleaf's vertically integrated global supply chain, enhancing its presence in the European medical cannabis market. The company aims to expand the Four 20 brand internationally, building on its success in Germany and existing launches in the UK and Poland.
Key Highlights
- Curaleaf completed the buyout of the remaining 45% stake in Four 20 Pharma GmbH.
- Four 20 Pharma is a fully EU-GMP and GDP licensed German medical cannabis producer and distributor.
- The acquisition strengthens Curaleaf's vertically integrated global supply chain and European market presence.
- Curaleaf has already launched the Four 20 brand in the United Kingdom and Poland.
- The company intends to continue expanding the Four 20 brand across additional international markets.